vTv Therapeutics Inc-A 2026年季度报告

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026Or For the transition period fromtoCommission file number: 001-37524 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) (Former name, former address and former fiscal year, if changed since last report)_____________________________ Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo Class of Stock Class A common stock, par value $0.01 per shareClass B common stock, par value $0.01 per share vTv THERAPEUTICS INC. AND SUBSIDIARIESINDEX TO FORM 10-QFOR THE QUARTER ENDED MARCH31, 2026 PART I – FINANCIAL INFORMATIONItem 1.Condensed Consolidated Balance Sheets as of March 31, 2026(Unaudited) and December 31, 20254Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2026and 20255Unaudited Condensed Consolidated Statement of Changes inStockholders’ Equity for the three monthsended March 31, 2026 and 20256Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026and 20257Notes to Unaudited Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3.Quantitative and Qualitative Disclosures About Market Risk25Item 4.Controls and Procedures25PART II – OTHER INFORMATIONItem 1.Legal Proceedings26Item 1A.Risk Factors26Item 2.Unregistered Sales of Equity Securities and Use of Proceeds26Item 3.Defaults Upon Senior Securities26Item 4.Mine Safety Disclosures26Item 5.Other Information26Item 6.Exhibits27Signatures28 Table of Contents PART I – FINANCIAL INFORMATION The financial statements and other disclosures contained in this report include those of vTv Therapeutics Inc. (“we”, the“Company” or the “Registrant”), which is the registrant, and those of vTv Therapeutics LLC (“vTv LLC”), which is the principaloperating subsidiary of the Registrant. Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to the“Company”, “we”, “us” and “our” refer to vTv Therapeutics Inc. and its consolidated subsidiaries. vTv Therapeutics Inc. Condensed Consolidated Balance Sheets (in thousands, except number of shares and per share data) vTv Therapeutics Inc. Condensed Consolidated Statements of Operations - Unaudited (in thousands, except number of shares and per share data) vTv Therapeutics Inc. Condensed Consolidated Statement of Changes in Stockholders’ Equity - Unaudited (in thousands, except number of shares) vTv Therapeutics Inc. Condensed Consolidated Statements of Cash Flows - Unaudited (in thousands) The accompanying notes are an integral part of the unaudited condensed consolidated financial statements. vTv Therapeutics Inc.Notes to Condensed Consolidated Financial Statements – Unaudited(dollar amounts are in thousands, unless otherwise noted) Note 1: Description of Business and Basis of Presentation Description of Business vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015.The Company is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to helptreat people living with diabetes and other chronic diseases. The Company’s clinical pipeline is led bycadisegliatin, currently in aPhase 3 trial, a potential first-in-class oral liver-selective glucokinase activator being investigated as an adjunctive